Cargando…

Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial

BACKGROUND: Ebolavirus and Marburgvirus cause severe hemorrhagic fever with high mortality and are potential bioterrorism agents. There are no available vaccines or therapeutic agents. Previous clinical trials evaluated transmembrane-deleted and point-mutation Ebolavirus glycoproteins (GPs) in candi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarwar, Uzma N., Costner, Pamela, Enama, Mary E., Berkowitz, Nina, Hu, Zonghui, Hendel, Cynthia S., Sitar, Sandra, Plummer, Sarah, Mulangu, Sabue, Bailer, Robert T., Koup, Richard A., Mascola, John R., Nabel, Gary J., Sullivan, Nancy J., Graham, Barney S., Ledgerwood, Julie E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318920/ https://www.ncbi.nlm.nih.gov/pubmed/25225676 http://dx.doi.org/10.1093/infdis/jiu511

Ejemplares similares

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

Evidence that ebolaviruses and cuevaviruses have been diverging from marburgviruses since the Miocene
por: Taylor, Derek J., et al.
Publicado: (2014)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

Unexpected Inheritance: Multiple Integrations of Ancient Bornavirus and Ebolavirus/Marburgvirus Sequences in Vertebrate Genomes
por: Belyi, Vladimir A., et al.
Publicado: (2010)

Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera
por: Jones, Megan E.B., et al.
Publicado: (2015)

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
por: Koup, Richard A., et al.
Publicado: (2010)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species
por: Hensley, Lisa E., et al.
Publicado: (2010)

A Chimeric Lloviu Virus Minigenome System Reveals that the Bat-Derived Filovirus Replicates More Similarly to Ebolaviruses than Marburgviruses
por: Manhart, Whitney A., et al.
Publicado: (2018)

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018)

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial
por: DeZure, Adam D., et al.
Publicado: (2017)

Recent advances in marburgvirus research
por: Olejnik, Judith, et al.
Publicado: (2019)

A New Approach for Monitoring Ebolavirus in Wild Great Apes
por: Reed, Patricia E., et al.
Publicado: (2014)

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018)

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial
por: Carter, Cristina, et al.
Publicado: (2019)

The roles of ebolavirus glycoproteins in viral pathogenesis
por: Ning, Yun-Jia, et al.
Publicado: (2016)

DNA Priming for Seasonal Influenza Vaccine: A Phase 1b Double-Blind Randomized Clinical Trial
por: Ledgerwood, Julie E., et al.
Publicado: (2015)

Marburgvirus in Egyptian Fruit Bats, Zambia
por: Kajihara, Masahiro, et al.
Publicado: (2019)

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
por: Gilchuk, Pavlo, et al.
Publicado: (2018)

P18-06. Increased HIV-specific immunity in HIV-infected individuals vaccinated with a DNA prime, rAd5 boost regimen
por: Casazza, JP, et al.
Publicado: (2009)

Characterization of Influenza Virus Pseudotyped with Ebolavirus Glycoprotein
por: Xiao, Julie Huiyuan, et al.
Publicado: (2018)

Glycan shield of the ebolavirus envelope glycoprotein GP
por: Peng, Weiwei, et al.
Publicado: (2022)

843. The PALM Consortium: A Multicenter, Multioutbreak Randomized Controlled Trial of Ebola Virus Disease Therapeutics
por: Mulangu, Sabue
Publicado: (2019)

Immunoinformatic and reverse vaccinology-based designing of potent multi-epitope vaccine against Marburgvirus targeting the glycoprotein
por: Yousaf, Hassan, et al.
Publicado: (2023)

Virus kinetics and biochemical derangements among children with Ebolavirus disease
por: Kjaldgaard, Lindsey, et al.
Publicado: (2022)

Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART
por: Riddler, Sharon A, et al.
Publicado: (2018)

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial
por: Houser, Katherine V., et al.
Publicado: (2018)

Similarity-Based Codes Sequentially Assigned to Ebolavirus Genomes Are Informative of Species Membership, Associated Outbreaks, and Transmission Chains
por: Weisberg, Alexandra J., et al.
Publicado: (2015)

Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region
por: Schoeder, Clara T., et al.
Publicado: (2022)

Expression of Ebolavirus glycoprotein on the target cells enhances viral entry
por: Manicassamy, Balaji, et al.
Publicado: (2009)

Serologic Markers for Ebolavirus Among Healthcare Workers in the Democratic Republic of the Congo
por: Hoff, Nicole A, et al.
Publicado: (2019)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Conservancy of mAb Epitopes in Ebolavirus Glycoproteins of Previous and 2014 Outbreaks
por: Ponomarenko, Julia, et al.
Publicado: (2014)

A Critical Domain of Ebolavirus Envelope Glycoprotein Determines Glycoform and Infectivity
por: Fujihira, Haruhiko, et al.
Publicado: (2018)

A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial
por: Martin, Julie E., et al.
Publicado: (2008)

Development of a model for marburgvirus based on severe-combined immunodeficiency mice
por: Warfield, Kelly L, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_5nnei2mrjg2snnj9qrjrobj8v0